Showing 1 - 2 results of 2 for search 'Robbert J Goekoop', query time: 0.01s Refine Results
  1. 1
    Multicentre, 26-week, open-label phase 2 trial of the JAK inhibitor filgotinib in Behçet’s disease, idiopathic inflammatory myopathies and IgG4-related disease: DRIMID study protocol

    Multicentre, 26-week, open-label phase 2 trial of the JAK inhibitor filgotinib in Behçet’s disease, idiopathic inflammatory myopathies and IgG4-related disease: DRIMID study protoc... by Sander W Tas, Joost Raaphorst, Paco M J Welsing, Jacob M van Laar, Rogier M Thurlings, Robbert J Goekoop, César Magro Checa, Jan A M van Laar, Bettina C Geertsema-Hoeve, Nicolle H Rekers, Erik Present

    Published 2025-02-01
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    Long-term safety and efficacy of the combination of belimumab and rituximab in the treatment of severe and refractory SLE: a preliminary report

    Long-term safety and efficacy of the combination of belimumab and rituximab in the treatment of severe and refractory SLE: a preliminary report by Tineke Kraaij, Cees van Kooten, Y K Onno Teng, Tom Huizinga, Eline J Arends, Robbert J Goekoop, Ton Rabelink, Mieke van Schaik, Marjolein J A L Wetzels, Stéphanie H Verbruggen, Sandra W van der Kooij, Sylvia W A Kamerling

    Published 2025-02-01
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: